Journal
JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS
Volume 9, Issue 1, Pages 258-261Publisher
ELSEVIER
DOI: 10.1016/j.jvsv.2020.04.001
Keywords
Lymphatic malformation; Sildenafil; Phosphodiesterase-5 inhibitor
Categories
Ask authors/readers for more resources
Sildenafil has shown benefit in treating some patients with complicated or refractory lymphatic malformations, leading to significant improvement in clinical symptoms.
Lymphatic malformations (LMs) are rare congenital anomalies. LMs are often refractory to standard treatments, including surgical resection, debulking, and sclerotherapy. Use of sildenafil, a phosphodiesterase-5 inhibitor, for treatment of pediatric LMs has been reported with demonstrated benefit to some patients. This case series reports treatment of three patients (aged 14-37 years) suffering from complicated or refractory LMs with a low-dose oral phosphodiesterase-5 inhibitor, resulting in significant clinical improvement.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available